196 related articles for article (PubMed ID: 32722909)
21. BLU enhances the effects of anti-angiogenic activity in combination with gemcitabine-based chemotherapeutic agents.
Yoo HJ; Kim BR; Byun HJ; Park SY; Rho SB
Int J Biochem Cell Biol; 2013 Jul; 45(7):1236-45. PubMed ID: 23579097
[TBL] [Abstract][Full Text] [Related]
22. Efficiency of recombinant human TNF in human cancer therapy.
Lejeune FJ; Liénard D; Matter M; Rüegg C
Cancer Immun; 2006 Mar; 6():6. PubMed ID: 16551058
[TBL] [Abstract][Full Text] [Related]
23. Epidermal growth factor receptor blockade with C225 plus gemcitabine results in regression of human pancreatic carcinoma growing orthotopically in nude mice by antiangiogenic mechanisms.
Bruns CJ; Harbison MT; Davis DW; Portera CA; Tsan R; McConkey DJ; Evans DB; Abbruzzese JL; Hicklin DJ; Radinsky R
Clin Cancer Res; 2000 May; 6(5):1936-48. PubMed ID: 10815919
[TBL] [Abstract][Full Text] [Related]
24. Blockade of vascular endothelial growth factor receptor and epidermal growth factor receptor signaling for therapy of metastatic human pancreatic cancer.
Baker CH; Solorzano CC; Fidler IJ
Cancer Res; 2002 Apr; 62(7):1996-2003. PubMed ID: 11929816
[TBL] [Abstract][Full Text] [Related]
25. Adenoviral transduction of human acid sphingomyelinase into neo-angiogenic endothelium radiosensitizes tumor cure.
Stancevic B; Varda-Bloom N; Cheng J; Fuller JD; Rotolo JA; García-Barros M; Feldman R; Rao S; Weichselbaum RR; Harats D; Haimovitz-Friedman A; Fuks Z; Sadelain M; Kolesnick R
PLoS One; 2013; 8(8):e69025. PubMed ID: 23936314
[TBL] [Abstract][Full Text] [Related]
26. Axitinib sensitization of high Single Dose Radiotherapy.
Rao SS; Thompson C; Cheng J; Haimovitz-Friedman A; Powell SN; Fuks Z; Kolesnick RN
Radiother Oncol; 2014 Apr; 111(1):88-93. PubMed ID: 24794795
[TBL] [Abstract][Full Text] [Related]
27. Sequencing of antiangiogenic agents in the treatment of metastatic colorectal cancer.
Lee JJ; Chu E
Clin Colorectal Cancer; 2014 Sep; 13(3):135-44. PubMed ID: 24768040
[TBL] [Abstract][Full Text] [Related]
28. PE, a new sulfated saponin from sea cucumber, exhibits anti-angiogenic and anti-tumor activities in vitro and in vivo.
Tian F; Zhang X; Tong Y; Yi Y; Zhang S; Li L; Sun P; Lin L; Ding J
Cancer Biol Ther; 2005 Aug; 4(8):874-82. PubMed ID: 16082187
[TBL] [Abstract][Full Text] [Related]
29. Inhibition of Endothelial SCUBE2 (Signal Peptide-CUB-EGF Domain-Containing Protein 2), a Novel VEGFR2 (Vascular Endothelial Growth Factor Receptor 2) Coreceptor, Suppresses Tumor Angiogenesis.
Lin YC; Liu CY; Kannagi R; Yang RB
Arterioscler Thromb Vasc Biol; 2018 May; 38(5):1202-1215. PubMed ID: 29545238
[TBL] [Abstract][Full Text] [Related]
30. Phase 1 pharmacogenetic and pharmacodynamic study of sorafenib with concurrent radiation therapy and gemcitabine in locally advanced unresectable pancreatic cancer.
Chiorean EG; Schneider BP; Akisik FM; Perkins SM; Anderson S; Johnson CS; DeWitt J; Helft P; Clark R; Johnston EL; Spittler AJ; Deluca J; Bu G; Shahda S; Loehrer PJ; Sandrasegaran K; Cardenes HR
Int J Radiat Oncol Biol Phys; 2014 Jun; 89(2):284-91. PubMed ID: 24726286
[TBL] [Abstract][Full Text] [Related]
31. Gemcitabine and vinorelbine combination chemotherapy for patients with advanced soft tissue sarcomas: results of a phase II trial.
Dileo P; Morgan JA; Zahrieh D; Desai J; Salesi JM; Harmon DC; Quigley MT; Polson K; Demetri GD; George S
Cancer; 2007 May; 109(9):1863-9. PubMed ID: 17385194
[TBL] [Abstract][Full Text] [Related]
32. The differential effects of metronomic gemcitabine and antiangiogenic treatment in patient-derived xenografts of pancreatic cancer: treatment effects on metabolism, vascular function, cell proliferation, and tumor growth.
Yapp DT; Wong MQ; Kyle AH; Valdez SM; Tso J; Yung A; Kozlowski P; Owen DA; Buczkowski AK; Chung SW; Scudamore CH; Minchinton AI; Ng SS
Angiogenesis; 2016 Apr; 19(2):229-44. PubMed ID: 26961182
[TBL] [Abstract][Full Text] [Related]
33. The influence of the schedule and the dose of gemcitabine on the anti-tumour efficacy in experimental human cancer.
Boven E; Schipper H; Erkelens CA; Hatty SA; Pinedo HM
Br J Cancer; 1993 Jul; 68(1):52-6. PubMed ID: 8318420
[TBL] [Abstract][Full Text] [Related]
34. A randomised, open-label, phase II study of neo/adjuvant doxorubicin and ifosfamide versus gemcitabine and docetaxel in patients with localised, high-risk, soft tissue sarcoma.
Davis EJ; Chugh R; Zhao L; Lucas DR; Biermann JS; Zalupski MM; Feng M; Wong SL; Jacobson J; Zyczynski L; Reinke D; Metko G; Baker LH; Schuetze SM
Eur J Cancer; 2015 Sep; 51(13):1794-802. PubMed ID: 26066736
[TBL] [Abstract][Full Text] [Related]
35. VEGFR2 heterogeneity and response to anti-angiogenic low dose metronomic cyclophosphamide treatment.
Patten SG; Adamcic U; Lacombe K; Minhas K; Skowronski K; Coomber BL
BMC Cancer; 2010 Dec; 10():683. PubMed ID: 21159176
[TBL] [Abstract][Full Text] [Related]
36. Efficacy and safety of gemcitabine plus docetaxel in Japanese patients with unresectable or recurrent bone and soft tissue sarcoma: Results from a single-institutional analysis.
Takahashi M; Komine K; Imai H; Okada Y; Saijo K; Takahashi M; Shirota H; Ohori H; Takahashi S; Chiba N; Mori T; Shimodaira H; Ishioka C
PLoS One; 2017; 12(5):e0176972. PubMed ID: 28489919
[TBL] [Abstract][Full Text] [Related]
37. Assessment of the platelet-derived growth factor receptor alpha antibody olaratumab in a panel of patient-derived soft tissue sarcoma xenografts.
Cornillie J; Wozniak A; Van Renterghem B; Van Winkel N; Wellens J; Gebreyohannes YK; Debiec-Rychter M; Sciot R; Hompes D; Schöffski P
BMC Cancer; 2019 Jul; 19(1):724. PubMed ID: 31331295
[TBL] [Abstract][Full Text] [Related]
38. Systemic management strategies for metastatic soft tissue sarcoma.
Movva S; Verschraegen C
Drugs; 2011 Nov; 71(16):2115-29. PubMed ID: 22035513
[TBL] [Abstract][Full Text] [Related]
39. VEGFR2-Targeted Contrast-Enhanced Ultrasound to Distinguish between Two Anti-Angiogenic Treatments.
Payen T; Dizeux A; Baldini C; Le Guillou-Buffello D; Lamuraglia M; Comperat E; Lucidarme O; Bridal SL
Ultrasound Med Biol; 2015 Aug; 41(8):2202-11. PubMed ID: 25980323
[TBL] [Abstract][Full Text] [Related]
40. Effects of the anti-VEGF monoclonal antibody bevacizumab in a preclinical model and in patients with refractory and multiple relapsed Hodgkin lymphoma.
Reiners KS; Gossmann A; von Strandmann EP; Böll B; Engert A; Borchmann P
J Immunother; 2009 Jun; 32(5):508-12. PubMed ID: 19609243
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
